(129) found that the concomitant inhibition of mTOR/PI3K, MEK1/2 and SRC, a non-receptor tyrosine kinase involved in cell mobility which is activated in LKB1-null cancers, can induce tumor regression and block metastasis in vivo (129). Here, STK11 is linked to cancer.